

Express Mail No. EV405281241US

INFORMATION DISCLOSURE STATEMENT Address to: Mail Stop PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	UCSF-077CON7
	First Named Inventor	MCDONALD, DONALD M.
	Application Number	To Be Assigned
	Confirmation No.	To Be Assigned
	Filing Date	April 2, 2004
	Group Art Unit	To Be Assigned
	Examiner Name	To Be Assigned
Title: "CATIONIC LIPID COMPOSITIONS TARGETING ANGIOGENIC ENDOTHELIAL CELLS"		

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.


All of the references identified herein were disclosed in parent application serial number 10/700,735 filed 11/3/2003 and 10/004,286 filed 11/14/2001, and as such, copies thereof are not included pursuant to the provisions of 37 CFR § 1.98(d).

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. § 102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. UCSF-077CON7 may be charged thereon.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: April 2, 2004

By: 
Paula A. Borden
Registration No. 42,344

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	To Be Assigned		
		Filing Date	November 3, 2003		
		First Named Inventor	McDonald		
		Group Art Unit	To Be Assigned		
		Examiner Name	To Be Assigned		
Sheet	1	of	1	Attorney Docket Number	UCSF-077CON6

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		6,426,086		Papahadjopoulos	July 30, 2002	
		6,271,206		Pillai	August 7, 2001	

FOREIGN PATENT DOCUMENTS								
Examiner Initials ¹	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/004,286
				Filing Date	November 14, 2001
				First Named Inventor	MCDONALD, DONALD M.
				Group Art Unit	1615
				Examiner Name	To be assigned
Sheet	1	of	1	Attorney Docket Number	UCSF-077CON2

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
		WO	93/18751	A	Rahman <i>et al.</i>	09-30-1993		
		WO	95/29242	A	O'Reilly <i>et al.</i>	11-02-1995		
		EP	0819758	A	Mixson	01-21-1998		

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CAMPBELL, <i>et al.</i> , "Cationic liposome mediated drug delivery", <i>Biophys. J.</i> , (1997) Vol. 72(2): A303 (WP313).	
		McLEAN, <i>et al.</i> , "Organ-specific endothelial cell uptake of cationic liposome-DNA complexes in mice", <i>Amer. J. Physiology</i> , Vol. 1, part 2, 273:H387-H404	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Notice of References Cited	Application/Control No. 10/004,286	Applicant(s)/Patent Under Reexam McDonald	
	Examiner Gollamudi Kishore	Art Unit 1615	Page 1 of 1

U.S. PATENT DOCUMENTS

	Document Number Country Code-Number-Kind Code	Date MM-YYYY ¹	Name	Classification ²
A				
B				
C				
D				
E				
F				
G				
H				
I				
J				
K				
L				
M				

FOREIGN PATENT DOCUMENTS

	Document Number Country Code-Number-Kind Code	Date MM-YYYY ¹	Country	Name	Classification ²
N					
O					
P					
Q					
R					
S					
T					

NON-PATENT DOCUMENTS

	Include, as applicable: Author, Title, Date, Publisher, Edition or Volume, Pertinent Pages
U	Wasan, E. K., Plasmid DNA is protected against ultrasonic cavitation-induced damage when complexed to cationic liposomes", Journal of Pharmaceutical Sciences, 85, # 4, pp. 427-433, April, 1996.
V	
W	
X	

* A copy of this reference is not being furnished with this Office action. See MPEP § 707.05(a).

¹ Dates in MM-YYYY format are publication dates.

² Classifications may be U.S. or foreign.

SUBSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. UCSF077CON2	SERIAL NO. 09/430,065
	APPLICANT: D. McDonald et al.		
	FILING DATE November 14, 2001	GROUP 1614	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	
	AA	4 3 9 4 4 4 8	07/19/83	Szoka, Jr. et al.			
	AB	4 8 9 7 3 5 5	01/30/90	Eppstein et al.			
	AC	5 0 9 2 8 8 5	03/03/92	Yamada et al.			
	AD	5 1 9 2 7 4 4	03/09/93	Bouck et al.			
	AE	5 2 0 2 3 5 2	04/13/93	Okada et al.			
	AF	5 3 2 8 4 7 0	07/12/94	Nabel et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	AG	WO 91/06309	05/16/91	PCT				
	AH	WO 93/12240	06/24/93	PCT				
	AI	WO 93/12756	07/08/93	PCT				
	AJ	WO 93/24640	12/09/93	PCT				
	AK	WO 93/25673	12/23/93	PCT				
	AL	WO 95/25543	09/28/95	PCT				

OTHER DOCUMENTS (including Author, Title, Date, Place of Publication).

	AM	Brigham, K.L., et al., (1989) "Expression of a Prokaryotic Gene in Cultured Lung Endothelial Cells after Lipofection with a Plasmid Vector," Am. J. Respir. Cell Mol. Biol. <u>1</u> : 95-100
	AN	Brigham, K.L., et al. (1989) "Rapid Communication: In vivo Transfection of Murine Lungs with a Functioning Prokaryotic Gene Using a Liposome Vehicle," from the Center for Lung Research, Dept. of Med. Path. and Molecular Phys. and Biophys., Vanderbilt U. School of Med., Nashville, Tenn. pp. 278-284
	AO	Burrows, F.J., et al., (1993) "Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature," Proc. Natl. Acad. Sci. USA <u>90</u> : 8996-9000
	AP	Felgner, P.L., et al., (1991) "Gene Therapeutics" Nature <u>349</u> : 351-352
	AQ	Felgner, P.L., et al., (1987) "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure," Proc. Natl. Acad. Sci. USA <u>84</u> : 7413-7417
	AR	Folkman, J., et al., (1989) "Induction of angiogenesis during the transition from hyperplasia to neoplasia," Nature <u>339</u> : 58-61
	AS	Folkman, J., et al., (1987) "Angiogenic Factors," Science <u>235</u> : 442-447
	BA	Gao, X., et al., (1995) "Cationic liposome-mediated gene transfer," Gene Therapy <u>2</u> : 710-722

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. UCSF077CON2	SERIAL NO. 09/430,065
		APPLICANT: D. McDonald et al.	
		FILING DATE November 14, 2001	GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

OTHER DOCUMENTS (including Author, Title, Date, Place of Publication).

BB	Hanahan, D., et al., (1996) "Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis," Cell 86: 353-364
BC	Huang, X., et al., (1997) "Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature," Science 275: 547-550
BD	Morishita, K., et al., (1995) "A novel promoter for vascular endothelial growth factor receptor (flt-1) that confers endothelial-specific gene expression," J. Biol Chem. 270: 27948-27953
BE	Xu, M., et al., "Parenteral Gene Therapy with p53 Inhibits Human Breast Tumors in Vivo Through a Bystander Mechanism Without Evidence of Toxicity," Human Gene Therapy 8:177-185.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

F:\DOCUMENT\UCSF\077con2\IDS 1449 .doc